Meredith R F, Johnson T K, Plott G, Macey D J, Vessella R L, Wilson L A, Breitz H B, Williams L E
Department of Radiation Oncology, University of Alabama, Birmingham 35233.
Med Phys. 1993 Mar-Apr;20(2 Pt 2):583-92. doi: 10.1118/1.597053.
Dosimetry data arising from a decade of radioimmunotherapy are summarized along with techniques utilized to arrive at the reported dose estimates. Generality of the MIRD methodology allows it to serve as a vehicle for the calculation of solid tumor dosimetry although several limitations exist. Nonstandard geometries of solid tumors will ultimately necessitate determination of absorbed fractions for the individual tumors. Several approaches currently under investigation are described. For reasons of practicality, solid tumor dosimetry estimates continue to use the assumption of homogeneous activity distribution in a source organ, accounting for either all radiation or only nonpenetrating radiation. As computation tools become available for incorporating inhomogeneous cellular level data, the currently used "average dose" as an index of tumor sterilization will likely be replaced with a statistical distribution based on the number of viable cells in the tumor volume. Estimates of a tumor control dose would be based upon a linear extension of dose coupled with a threshold dose for cell sterilization.
总结了十年来放射免疫治疗产生的剂量测定数据以及用于得出报告剂量估计值的技术。MIRD方法的通用性使其能够作为计算实体瘤剂量测定的工具,尽管存在一些局限性。实体瘤的非标准几何形状最终将需要确定各个肿瘤的吸收分数。描述了目前正在研究的几种方法。出于实际原因,实体瘤剂量测定估计继续采用源器官中活性分布均匀的假设,可考虑所有辐射或仅非穿透性辐射。随着用于纳入非均匀细胞水平数据的计算工具的出现,目前作为肿瘤灭活指标的“平均剂量”可能会被基于肿瘤体积中活细胞数量的统计分布所取代。肿瘤控制剂量的估计将基于剂量的线性延伸以及细胞灭活的阈值剂量。